Last checked at (Sharecast News) - Hutchison China MediTech announced on Friday that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted 'Priority Review' status to its new drug application for 'surufatinib', for the treatment of patients with advanced non-pancreatic neuroendocrine tumours.
The AIM-traded firm noted that in November, the new drug application for surufatinib for the treatment of non-pancreatic neuroendocrine tumours was accepted for review by the NMPA.
At the same time, the United States Food and Drug Administration granted 'orphan drug designation' to surufatinib for the treatment of pancreatic neuroendocrine tumours.
"Surufatinib is our second drug to be granted priority review by the NMPA," said Hutchison Chi-Med chief executive officer Christian Hogg.
"We are working closely with the NMPA as they review our NDA for the treatment of non-pancreatic neuroendocrine tumours.
"Surufatinib being granted priority review is a positive step forward in potentially bringing this innovative drug to patients, who currently have very limited treatment options."
At 1543 GMT, shares in Hutchison China MediTech were up 1.87% at 381p.
3 Dec 2021 13:23
Two Hutchmed drugs included in China's 2022 reimbursement list
(Sharecast News) - Hutchmed China announced on Friday that, following negotiations with the China National Healthcare Security Administration (NHSA), from 1 January the updated National Reimbursement Drug List (NRDL) will continue to include 'Elunate', or fruquintinib, and would now include 'Sulanda', or surufatinib.
Read more